title: [Repressional effects of the glutamate antibodies on expression of Dffb gene in the brain of rats with experimental Alzheimer's disease].
abstract: The intranasal administration of glutamate antibodies in the dose of 300 microg/kg one hour after damage on the level of mRNA expression of Dffb gene which codes caspase-activated DNase which participates in intranucleosome fragmentation of genome DNA in apoptosis was investigated in experimental Alzheimer's disease induced by injection of neurotoxic fragment of beta-amyloid protein Abeta25-35 in Meynert basal magnocellular nuclei on rats. On the Day 3 after Abeta25-35 injection is observed significant decrease of the level of mRNA expression of Dffb gene in prefrontal cortex in 37%, and in hippocampus in 62% in the experiment group versus the control group. These differences were not found in the hypothalamus when comparing the experimental and control animals. It was suggested that repressive effect of glutamate antibodies on the level of mRNA expression of Dffb gene reflects stabilization of processes taking place in brain cells in experimental Alzheimer's disease, and in its turn the intensiveness of nerve and glial cells apoptotic death is decreased.
authors.forename: V V
authors.initials: VV
authors.lastname: Kolobov
authors.forename: T V
authors.initials: TV
authors.lastname: Davydova
authors.forename: I A
authors.initials: IA
authors.lastname: Zakharova
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Gorbatov
authors.forename: V G
authors.initials: VG
authors.lastname: Fomina
mesh_terms: D000281:Administration, Intranasal; D000544:Alzheimer Disease / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000008:administration & dosage; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D020532:Basal Nucleus of Meynert / Q000187:drug effects / Q000473:pathology; D002540:Cerebral Cortex / Q000187:drug effects* / Q000378:metabolism; D003851:Deoxyribonucleases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D015870:Gene Expression / Q000187:drug effects; D018698:Glutamic Acid / Q000276:immunology; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007276:Injections, Intraventricular; D008297:Male; D000075223:Poly-ADP-Ribose Binding Proteins; D012333:RNA, Messenger / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar
chemical_list: D016229:Amyloid beta-Peptides; D000906:Antibodies; D000075223:Poly-ADP-Ribose Binding Proteins; D012333:RNA, Messenger; D018698:Glutamic Acid; D003851:Deoxyribonucleases; C491882:Dffb protein, rat